Hepatocellular Carcinoma
Phase III study in hepatocellular carcinoma fails to achieve primary endpoint
Published in Drug Week, September 2nd, 2005
Additional analyses will be conducted with the data from the phase III study, also known as ETHECC (evaluation of THYMITAQ in hepatocellular carcinoma), to better understand the results of the survival analysis and future activities.
Eximias Pharmaceutical Corp. has an experienced management team and a strong cash position, having completed a $63.5 million financing round in 2004, and is continuing to evaluate...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2005-09-02)
More Articles from Drug Week
- Breast Cancer
Beta-tubulin isotype alterations linked to docetaxel resistance - Drug Delivery
Data on ways to improve Fuzeon presented at meeting - Drug Development
Two additional sites initiated for phase II trial of ADH-1 - HIV/AIDS Therapy
Positive Thiovir data presented at IAS 2005 conference - Acromegaly
Acute octreotide test doesn't predict long-term Sandostatin LAR efficacy - Acute Pulmonary Embolism
Company gets approval for Cleactor Inj in Japan - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
